Beta

Dermata therapeutics, inc.DRMA.US Overview

US StockHealthcare
(No presentation for DRMA)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

DRMA AI Insights

DRMA Overall Performance

DRMA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DRMA Recent Performance

4.13%

Dermata therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

DRMA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check DRMA's Trend

DRMA Key Information

DRMA Valuation Metrics

DRMA Profile

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Price of DRMA

DRMA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DRMA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-11.09
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.80
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-11.09
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.80
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is DRMA's latest earnings report released?

    The most recent financial report for Dermata therapeutics, inc. (DRMA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DRMA's short-term business performance and financial health. For the latest updates on DRMA's earnings releases, visit this page regularly.

  • How much cash does DRMA have?

    At the end of the period, Dermata therapeutics, inc. (DRMA) held Total Cash and Cash Equivalents of 7.52M, accounting for 0.96 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is DRMA's EPS continuing to grow?

    According to the past four quarterly reports, Dermata therapeutics, inc. (DRMA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.52. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DRMA?

    Dermata therapeutics, inc. (DRMA)'s Free Cash Flow (FCF) for the period is -1.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 54.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of DRMA?

    The latest valuation data shows Dermata therapeutics, inc. (DRMA) has a Price-To-Earnings (PE) ratio of -0.73 and a Price/Earnings-To-Growth (PEG) ratio of 0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.